| Code | 2562D | ||||||||||
| MA number | 44/0323/19-S | ||||||||||
| Product Form: | tbl flm 60x140 mg (blis.OPA/Al/PVC/Al) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | blister OPA/Al/PVC/Al | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 09.10.2019 |
| Validity: | 09.10.2024 |
| MA renewed: | Renewal application submitted |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| PIL: |
PIL_Dasatinib Krka 140 mg filmom obalené tablety_10.2022.pdf
|
| SPC: |
SPC_Dasatinib Krka 140 mg filmom obalené tablety_09.2023.pdf
|
| Safety feature | Yes |
| Data update: | 08.03.2022 |
